关键数据
2.610今开
2.870最高
72.03K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.17%换手率
2.560昨收
2.555最低
199.17K成交额
亏损市盈率静
3.51市净率
0.00%股息率 TTM
-39.31%ROA
3.25052周最高
0.08量比
-56.39M净利润
42.95M总股本
-1.2916每股收益TTM
0.27Beta
-86.22%ROE
1.13052周最低
17.97%振幅
76.19%毛利率
120.26M总市值
14.03回报/风险
6.24%风险率

即将为您带来更多新闻,敬请期待。。。
Pulmonx Corp评分
0.13与上次评分对比预测7.60
财务诊断6.55
技术分析6.92
公司估值7.80
机构认同度7.00
风险评估2.27
分析师评级
Pulmonx Corp 最新财报电话会记录
Pulmonx (LUNG) 2026财年第三季度业绩电话会:营收重回增长
Pulmonx 2026年第三季度营收增长6%至2280万美元,调整后EBITDA亏损收窄近60%。管理层重申了9000万至9200万美元的业绩指引。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Pulmonx Corp 简介
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
行业医疗设备与耗材
公司代码LUNG
员工数量291
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| PRIMECAP Management Company | 11.19% |
|---|
| Morgan Stanley & Co. LLC | 9.21% |
|---|
| Soleus Capital Management, L.P. | 6.31% |
|---|
| BlackRock Institutional Trust Company, N.A. | 5.82% |
|---|
| 股东类型 | 占比 |
|---|
| Investment Advisor | 33.62% |
|---|
| Hedge Fund | 21.60% |
|---|
| Investment Advisor/Hedge Fund | 13.04% |
|---|
| Research Firm | 12.57% |
|---|
常见问题
Pulmonx Corp(LUNG)的当前股价是多少?
Pulmonx Corp(LUNG)的当前股价是 2.80。
Pulmonx Corp股票的52周最高点是多少?
Pulmonx Corp股票的52周最高点是3.25。
Pulmonx Corp股票的52周最低点是多少?
Pulmonx Corp股票的52周最低点是1.13。
现在Pulmonx Corp(LUNG)的股票是买入、持有还是卖出?
根据分析师评级,Pulmonx Corp(LUNG)的总体评级为买入,目标价格为3.62。
Pulmonx Corp(LUNG)股票的每股收益(EPS TTM)是多少
Pulmonx Corp(LUNG)股票的每股收益(EPS TTM)是-1.29。